Dr. Lefer is currently a Professor of Surgery at the Emory University School of Medicine and is Director of the Cardiothoracic Surgery Research Labs in the Division of Cardiothoracic Surgery.  His research is focused on the investigation and translation of the cardioprotective therapies for the treatment of acute myocardial infarction and congestive heart failure. Dr. Lefer has performed seminal research in the areas of statin-mediated and nitric oxide mediated cardioprotection in the setting of myocardial infarction and heart failure. Dr. Lefer is an expert in the field of nitric oxide and nitrite physiology and cytoprotection and his research team was among the first to demonstrate the profound cardioprotective effects of sodium nitrite in ischemia-reperfusion injury in preclinical model systems.  Dr. Lefer has also served as a cardiovascular consultant for Merck and Company, Pfizer Global Research, Syngenta, Forest Research Institute, Cytel, Genentech, Texas Biotechnology, Biopure, Ikaria, Adolor, Astra-Zeneca, Genetics Institute, Schwarz Pharma, and Boehringer Ingelheim.

Dr. Flanagan is a Professor of Pharmaceutics and Chemical & Biochemical Engineering and former Division Head of the Pharmaceutics Division in the College of Pharmacy at the University of Iowa.  With nearly 90 publications and over 100 presentations at scientific meetings, Dr. Flanagan has 40 years experience teaching about and developing drug formulations and biopharmaceutics. He has had numerous collaborative grants with government agencies and partnerships with pharmaceutical companies such as Bristol-Myers Squibb, Abbott Laboratories, Axonyx, and over 25 other firms, working on controlled drug delivery systems and formulations.  Many of these collaborative efforts and partnerships have come through his over 30 year relationship with the University of Iowa Pharmaceuticals (UIP). UIP is a FDA-registered clinical manufacturer which has provided to formulation development and production services to the pharmaceutical industry and government agencies for over 40 years.

Dr. Annex has had a long standing clinical and basic research interest in area of angiogenesis (the growth of new blood vessels) in peripheral arterial disease (PAD). PAD is caused by blockages in arteries to the leg. His group conducts a series of translational studies in PAD which include investigations on the causes of lower extremity atherosclerosis, the mechanisms that regulate the control of collateral blood vessel formation, the impact that diabetes mellitus plays in PAD, computational modeling of growth factor pathways, as well as genetic influences. There are several clinical studies such as those testing the mechanism of exercise training as well as gene or cell based clinical investigation to promote blood vessel growth in patients with PAD. Finally, Dr. Annex is a well known thought leader in the PAD and clinical trials. Dr. Annex currently serves as the Chief of the Division of Cardiovascular Medicine at the University of Virginia.

Dr. Soin is chairman and founder of The Ohio Pain Clinic- a network of free-standing chronic pain management facilities in southwestern Ohio focused on non opioid based treatments for chronic pain. He brings a wealth of experience in research, development, biotech angel investing, and regulatory matters to TheraVasc. Currently, he is a physician representative to Medicare via the Clinical Advisory Committee for Ohio and West Virginia. Additionally, he has held several key leadership positions in various statewide and national medical societies. Dr. Soin has authored several papers, textbook chapters, abstracts, and served as a primary investigator for clinical research. He is also the founder and CEO of a biotech angel investment firm and has experience creating viable medical products from bench research. Dr. Soin serves as a Clinical Assistant Professor of Surgery at Wright State University Medical School and was selected as one of America's Top Doctors in Pain Management for 2006, 2007, 2008, and 2009. He has also won the "Patients Choice Award" in 2008 and 2009 and the “Top Doctors and Patient Choice Award" for 2010. Dr. Soin trained at the Cleveland Clinic, and currently he is an active practicing physician who sees patients that suffer from painful peripheral artery disease and poor wound healing on a daily basis. He is also an observer on the board of directors.

Mr. Gill is a Regulatory, QA, QC Compliance Consultant with an extensive knowledge of quality assurance, cGLP, cGMP quality control systems, chemistry, manufacturing and controls requirements, and an expert in general FDA Regulatory requirements with 26 years of experience in the U.S. pharmaceutical industry working for international pharmaceutical companies. Mr. Gill began his career as an analytical chemist for Boots Pharmaceuticals, Inc., then transitioned into the Regulatory Affairs department where he worked in the R&D group managing INDs for the cardiovascular and anti-depressant drug product portfolios. Mr. Gill then worked as a Regulatory and Compliance Manager for BASF Corportion, the US subsidiary of the German chemical company and subsequently as a Regulatory and Compliance Manager for Dr. Reddys Laboratories, Inc., an Indian based generic drug leader in the world generic market. Mr. Gill successfully lead transition teams for the introduction of foreign manufactured drug product and transfer of the manufacturing of those products from foreign plants to US manufacturing facilities for the US market for oral solutions, creams and solid oral dosage forms. Mr. Gill has had extensive experience in managing US FDA, EU and German regulatory authority inspections for US manufacturing facilities.